Welcome to the Investor Relations section of the Ergomed website.


This area is dedicated to keeping shareholders and potential investors up to date with share price, news and other relevant information.

TR-1 Forms should be sent to ir@ergomedplc.com

Last Update

28 January 2019

Stock Code

ERGO

No of Shares in Issue

45,016,438

Accounting Year End

31 December

Country of Registration

England

Main Country of Operation

UK

Date Listed

15 July 2014

Index Market

AIM

Ergomed offers a comprehensive suite of specialised services to the pharmaceutical industry. In our Clinical Research Services division, we undertake on behalf of our clients all facets of clinical trial management, from Phase I to IV. In our Drug Safety and Medical Information division we provide a range of services related to the collection, aggregation and reporting of safety issues related to drugs on the market, sometimes called pharmacovigilance. In addition, Ergomed has a drug development portfolio of co-development partnerships and wholly-owned programmes.  The Ergomed group operates out of 20 offices across the globe.

Clinical Research Services

Over 20 years Ergomed has built particular expertise in oncology, neurology, immunology and the development of orphan drugs. Our approach is differentiated from other providers through our innovative Site Management model and Study Physician teams, resulting in a closer and more productive relationship between Ergomed and investigational sites involved in clinical trials. Ergomed Clinical Research Services is conducting clinical trials in 55 countries.

Drug Safety and Medical Information

Through our subsidiary PrimeVigilance, we offer the full range of drug safety and medical information services including adverse event case processing, aggregate reporting, risk management plans, signal detection and audit. PrimeVigilance, including the recently re-branded PharmInvent, is a medically led organisation with a passion for quality. This is reflected in our exceptional client retention and organic growth. PrimeVigilance is currently monitoring drugs in over 100 countries for more than 100 clients (see: www.primevigilance.com).

Drug Development

We have a portfolio of four active co-development partnerships with pharmaceutical and biotech companies in which we share the risks and rewards of drug development with our partners. In addition, our Haemostatix subsidiary is developing two wholly-owned products for the treatment of surgical bleeding (see: www.haemostatix.com).

ERGOMED
The Surrey Research Park
1 Occam Court
Guildford, Surrey GU2 7HJ
United Kingdom

Board of Directors

Dr Miroslav Reljanović

Founder and Executive Chairman

Dr Miroslav Reljanović

Founder and Executive Chairman

Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. Miro founded Ergomed in 1997 and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies.

Miro successfully introduced the first European co-development business model and he has completed several partnerships with European and North American listed biopharmaceutical companies. Miro co-founded PrimeVigilance in 2008 and it soon became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry.

Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange in July 2014 and the subsequent completion of five acquisitions and a secondary offering.

Miro is a director of Asarina Pharma AB (listed on the Nasdaq First North exchange), and Modus Therapeutics Holding AB, both Swedish-incorporated companies in which Ergomed plc has an equity stake through co-development arrangements.

Miro brings to the Board his in-depth experience in clinical development and the operational execution of drug development, as well as a detailed knowledge of the Group and its
operations.

Miro is Chair of Ergomed’s Nomination Committee.

Dr Jan Petracek

Chief Operating Officer

Dr Jan Petracek

Chief Operating Officer

Dr. Jan Petracek was appointed to the Board as Chief Operating Officer in December 2017 and has been Chief Executive Officer of PrimeVigilance since April 2017. He joined the Ergomed group in November 2016 following the acquisition of European PharmInvent Services s.r.o., where he was founder and CEO. Dr. Petracek is the former Head of Risk Management at the European Medicines Agency and the former Head of Pharmacovigilance, Strategy and Development at the State Institute for Drug Control in the Czech Republic. Dr. Petracek was the EU Qualified Person responsible for pharmacovigilance at Vertex Pharmaceuticals, Biogen and BluePrint Medicines.

Dr. Petracek studied Quality and Safety in Healthcare (MSc) at Imperial College London and trained as a physician at Charles University in Prague (MD).

Dr. Petracek sits on the Advisory Board of the International Society of Pharmacovigilance and is a regular speaker at international pharmacovigilance conferences and training seminars.

Dr. Petracek keeps his skillset up-to-date by attending pharmacovigilance conferences and courses, and attending leadership coaching and business mentoring sessions.

As the founder of several successful organisations, Dr. Petracek brings entrepreneurship, business acumen and a track record of innovation in pharmacovigilance to the Board. As a senior ex-regulator, he has a deep understanding of the pharmaceutical regulatory environment.

Richard Barfield

Chief Financial Officer

Richard Barfield

Chief Financial Officer

Richard joined Ergomed as Chief Financial Officer in June 2019. Since qualifying as a chartered accountant, Richard has more than 25 years’ experience at Chief Financial Officer level in the healthcare, technology and business services sectors in US multinational companies as well as in UK-listed and PE-backed businesses. His expertise includes turnarounds, fundraisings, acquisitions and disposals, and he has extensive international experience. Richard has also held roles as Chief Executive Officer, Chairman, and Audit Committee Chairman of UK-listed companies as well as serving as a Board Member of an NHS Foundation Trust.
Richard has proven experience within the contract research sector, having most recently been Chief Financial Officer at Chiltern International Ltd from July 2013 to March 2018, which was a leading global mid-tier private CRO. During his five years at Chiltern, Richard was instrumental in transforming the corporate finance and strategy of the business, enabling it to grow revenues from $160m to $550m and deliver significant returns to its investors.

Peter George

Non-executive and Senior Independent Director

Peter George

Non-executive and Senior Independent Director

Peter George joined Ergomed as a non-executive director in May 2014. He became Ergomed’s Senior Independent Director in February 2019, having served as Non-Executive Chairman from April 2017 to January 2019.

Peter has over 20 years’ experience in the pharmaceutical services industry, most recently as Chief Executive Officer of Clinigen Group plc, the AIM-listed global speciality pharmaceuticals and pharmaceutical services business. Peter stepped down as CEO of Clinigen in November 2016. Prior to Clinigen, Peter was CEO at Penn Pharma, having led a £67 million management buy-out of the company in 2007.

Before this, Peter was executive Vice President for Wolters Kluwer Health with responsibility for Europe and Asia Pacific regions. Peter has also held roles as the Chief Operating Officer of Unilabs Clinical Trials International Limited, Head of Clinical Pathology in the Oxford region of the NHS and as a director of PharmaPatents Global.

Peter is currently Chair of Benchmark Holdings plc and Entrepreneur in Residence at Oxford Sciences Innovation.

He is also President of Enigma Holdings Ltd and Chairman of Mitre Group Limited, XPG Ltd, Marco Polo Events Limited, and Rent Plus Ltd, companies he owns or has significant holdings in.

Peter’s technical, commercial and business expertise in pharmaceutical services and experience of the AIM market environment enable him to provide valued guidance to the Board.

Peter is a member of Ergomed’s Audit and Risk Committee, Remuneration Committee and Nomination Committee.

Michael Spiteri

Non-Executive Director

Michael Spiteri

Non-Executive Director

Michael has held a number of senior leadership positions in the consulting industry and financial services industry over a 25 year period. He specialises in helping organisations implement technology that transforms their business and operating models and is currently the Global COO for Digital, Data and Development in HSBC’s Retail Banking and Wealth Management business.

Michael was previously a partner at PwC and held senior leadership positions at Accenture and IBM. He was involved in the early stages of telematics and the development of automation technology and business models in insurance and telecoms. Michael has a degree in Mechanical Engineering and designed real time computer solutions in the oil and gas industry in the early part of his career.

Michael brings his extensive experience in technological innovation to help the Board develop Ergomed’s business across digital, automation and machine learning.

Michael is a member of Ergomed’s Audit and Risk, Remuneration and Nomination Committees.

Rolf Soderstrom

Non-Executive Director

Rolf Soderstrom

Non-Executive Director

Rolf Soderstrom has over 30 years’ experience in finance and a track record of  accelerating the profitable growth of companies and delivering shareholder returns. Rolf has extensive strategic, operational and international experience including M&A, fundraisings and disposals.

During his time as CFO of BTG plc from 2008 to 2018, Rolf helped drive the successful transformation of the company into a fully integrated global manufacturing and sales organisation focused on specialist healthcare. As a key member of the leadership team he helped BTG grow from a small UK based business with 60 employees, to a global business with more than 1,500 people across North America, Asia and Europe. During this period the share price outperformed the FTSE 250 and the market capitalisation increased from approximately £400 million to £3 billion driven by a combination of organic growth and acquisitions.

Before joining BTG Rolf was Divisional Finance Director at Cobham Plc from 2004 to 2007 where he was responsible for a portfolio of 17 companies in Europe and the United States with combined turnover of £400 million. Prior to this he was Director of Corporate Finance at Cable & Wireless Plc. He qualified as a chartered accountant at PricewaterhouseCoopers where he worked initially in audit and then in the corporate finance function.

Rolf is Chair of Ergomed’s Audit and Risk Committee and a member of its Remuneration Committee.

Dr. James Esinhart

Non-Executive Director

Dr. James Esinhart

Non-Executive Director

Dr. James Esinhart is an experienced leader in the clinical research industry with over 30 years working in biopharmaceutical companies, academia, and global clinical research organizations.

Most recently, Dr. Esinhart joined Chiltern International in 2006 and became CEO in 2012. Under his leadership, Chiltern was firmly established as a leading global mid-market CRO through the expansion of the company’s international footprint, multiple acquisitions and strategic investment in processes, people and technology. From 2006 to 2017 Chiltern’s growth was more than 11x, with revenue growing to over $550m and the global workforce to over 4,500. His successful tenure culminated in the sale of Chiltern to Covance, a division of the US-listed healthcare company Laboratory Corporation of America Holdings (LabCorp) in late 2017 for $1.2bn.

Dr. Esinhart has previously held several leadership positions in clinical research, including Vice President of Medical Data Sciences at Charles River and Inveresk. Prior to this time, he was co-founder and Senior Vice President of Biometrics at PharmaResearch Corporation. He was Assistant Professor at East Carolina University School of Medicine and also served on the university’s internal review board (IRB) for all research involving human subjects. In addition, he worked in clinical biostatistics product development roles at GlaxoSmithKline and Wyeth.

Dr Esinhart holds a PhD in Biostatistics from Virginia Commonwealth University School of Medicine in Richmond, Virginia, and a BS in Statistics from Radford University.

Dr. Esinhart is Chair of Ergomed’s Remuneration Committee.

Ian Johnson

Non-Executive Director

Ian Johnson

Non-Executive Director

Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006. Most recently Ian was Executive Chairman of Bioquell PLC, which was acquired by Ecolab Inc. in January 2019.  Prior to this Ian was non-executive Chairman of Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd. He has also served on the boards of various other public and private companies including Aim listed companies; Evans Analytical Group, MyCelx Technologies Corporation and AOI Medical Inc.

Ian studied at Cardiff University obtaining a B.Sc. and M.Sc. in Microbiology. He is a chartered biologist, a member of the Institute of Biology and the Institute of Directors.

Sanja Jurić

General Counsel and Company Secretary

Sanja Jurić

General Counsel and Company Secretary

Sanja Juric joined Ergomed in 2016 after more than 30 years’ career in international law and after having assisted Ergomed as its outside advisor for more than 15 years. As Ergomed’s counsel, Sanja has been on Ergomed core co-development team since the first deal and helped close several co-development transactions.

Sanja holds degrees from the University of Zagreb (LLB, 1985) and the University of Fordham, School of Law, New York City (LLM in International Trade and Business Law, 1992). She has been admitted to the Bar of the State of New York since May 1993 and is listed as an arbitrator with the Chamber of Commerce in Croatia.

Sanja’s experience encompasses both in-house positions, including that of the head of legal affairs of the largest Croatian private company, during the period of its intense expansion via acquisitions and law firm positions. Prior to joining Ergomed, Sanja provided consulting to international businesses and organizations (including IFC, DEG, Avon, Kleeman, Herbalife) and cooperated with multinational law firms (Baker & McKenzie) focusing on cross-border transactions, primarily M&A. Sanja wrote extensively for several international M&A handbooks and participated for many years as an author in the World Bank series of “Doing Business”.

The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies.

Ergomed offers a comprehensive suite of specialised services to the pharmaceutical industry. In our Clinical Research Services division, we undertake on behalf of our clients all facets of clinical trial management, from Phase I to IV. In our Drug Safety and Medical Information division we provide a range of services related to the collection, aggregation and reporting of safety issues related to drugs on the market, sometimes called pharmacovigilance. In addition, Ergomed has a drug development portfolio of co-development partnerships and wholly-owned programmes.  The Ergomed group operates out of 20 offices across the globe.

Clinical Research Services

Over 20 years Ergomed has built particular expertise in oncology, neurology, immunology and the development of orphan drugs. Our approach is differentiated from other providers through our innovative Site Management model and Study Physician teams, resulting in a closer and more productive relationship between Ergomed and investigational sites involved in clinical trials. Ergomed Clinical Research Services is conducting clinical trials in 55 countries.

Drug Safety and Medical Information

Through our subsidiary PrimeVigilance, we offer the full range of drug safety and medical information services including adverse event case processing, aggregate reporting, risk management plans, signal detection and audit. PrimeVigilance, including the recently re-branded PharmInvent, is a medically led organisation with a passion for quality. This is reflected in our exceptional client retention and organic growth. PrimeVigilance is currently monitoring drugs in over 100 countries for more than 100 clients (see: www.primevigilance.com).

Drug Development

We have a portfolio of four active co-development partnerships with pharmaceutical and biotech companies in which we share the risks and rewards of drug development with our partners. In addition, our Haemostatix subsidiary is developing two wholly-owned products for the treatment of surgical bleeding (see: www.haemostatix.com).

Audit and Risk Committee

The Audit and Risk Committee has Rolf Soderstrom as chair, and has primary responsibility for monitoring the quality of internal controls, ensuring that the financial performance of the Company is properly measured and reported on and reviewing reports from the Company’s auditors relating to the Company’s accounting and internal controls, in all cases having due regard to the interests of Ergomed’s shareholders.

The Audit and Risk Committee is also responsible for ensuring that the Company is complying with the AIM rules and its corporate governance obligations and for assessing the Company’s corporate governance practices.

The Audit and Risk Committee meets at least twice a year. Peter George and Michael Spiteri are the other members of the Audit and Risk Committee.

Remuneration Committee

The Remuneration Committee has Jim Esinhart as Chair, and reviews the performance of the executive directors and determines their terms and conditions of service, including their remuneration and the grant of options, having due regard to the interests of shareholders.

The Remuneration Committee meets at least twice a year. Peter George, Michael Spiteri and Rolf Sodorstrom are the other members of the Remuneration Committee.

Nomination Committee

The Nomination Committee has Dr. Miroslav Reljanovic as Chair, and identifies and nominates for the approval of the Board, candidates to fill board vacancies as and when they arise.

The Nomination Committee meets at least twice a year. Peter George and Michael Spiteri are the other members of the Nomination Committee.

Number of Ordinary Shares in issue: 45,016,438 (last updated  28 June 2019)

Shareholder  Analysis as of 28 June 2019

Shares not in public hands (including shares held by Directors): 27.04%

Significant shareholders:

Dr. Miroslav Reljanović 23.88%
Harwood Capital 13.07%
Slater Investments 9.85%
BlackRock 8.63%
GVQ Investment Management 7.10%
Gresham House Asset Management 6.08%
Octopus Investments 4.18%
Rathbones 3.79%
Fullbrook Thorpe Investments 3.11%
Business Growth Fund 3.06%

 

TR-1 Forms should be sent to ir@ergomedplc.com

In addition to the AIM market, the Company’s shares are also traded on Xetra, the electronic trading system of Deutsche Börse AG in Germany. The ISIN is GB00BN7ZCY67 and the ticker symbol is ZEMGR.

The Company is subject to the UK City Code on Takeovers and Mergers

This information is being provided for AIM Rule 26 compliance

The Board of Ergomed plc recognises the importance of sound corporate governance and has adopted the QCA Corporate Governance Code (published in April 2018 by the Quoted Companies Alliance). The QCA Corporate Governance Code states that “Companies need to deliver growth in long-term shareholder value. This requires an efficient, effective and dynamic management framework and should be accompanied by good communication which helps to promote confidence and trust”.

Ergomed’s Corporate Governance Statements, explain how Ergomed complies with the ten principles of the QCA Corporate Governance Code and are updated annually.

Ergomed’s Corporate Governance Statements are available here:

Corporate Governance Statement 2019

Corporate Governance Statement 2018

Nominated Adviser & Joint Broker

Numis Securities Limited
10 Paternoster Square
London
EC4M 7LT

Solicitors to the Company

Covington & Burling LLP
265 Strand
London
WC2R 1BH

Registrars

Share Registrars Limited
The Courtyard, 17 West Street
Farnham, Surrey
GU9 7DR

Auditor

KPMG
1 Stokes Place
St. Stephen’s Green
Dublin 2
Ireland

Financial PR (UK)

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

Financial PR (Continental Europe)

MC Services AG
Kaiser Friedrich Ring 5
40545 Dusseldorf
Germany

The below analyst follows Ergomed. To obtain a copy of their research report(s), please contact as per below.

Numis Securities Limited

Stefan Hamill

Millions of people fall victim to scams every year, from experienced investors to people dealing with a large sum for the first time. They may offer to sell shares that turn out to be worthless or non-existent, or to buy shares at an inflated price in return for an upfront payment. While high profits are promised, if you buy or sell shares in this way you will probably lose your money.

‎In particular, it has come to our attention that individuals have been sent letters purporting to come from Ergomed, together with a contract note asking for payment to be made to an account in settlement of a share purchase. These are not from Ergomed and the adviser referred to in these letters, Applied Finance Group, has not been engaged by Ergomed for any purposes and you should not transfer any money to them.

Protect yourself

Investment scams are designed to look like genuine investments. You should take these steps to spot and avoid them before handing over any money:

  1. You should treat any call, email or letter with extreme caution. Get the name of the person and the organisation contacting you.
  2. Check the FCA Warning List to ensure they are authorised.
  3. Use the details on the Financial Services Register to contact the firm.
  4. Call the FCA Consumer Helpline on 0800 111 6768 if there are no contact details on the Register or you are told they are out of date.
  5. Search the list of unauthorised firms and individuals to avoid doing business with at www.fca.org.uk scams

Report a scam

If you think you have been contacted by fraudsters you should tell the FCA using the share fraud reporting form or call the FCA Consumer Helpline on 0800 111 6768.‎

If you have lost money to investment fraud, you should report it to Action Fraud on 0300 123 2040 or online at www.actionfraud.police.uk